Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation

Yu, 2012, Ivacaftor potentiation of multiple CFTR channels with gating mutations, J Cyst Fibros, 11, 237, 10.1016/j.jcf.2011.12.005 Ramsey, 2011, A CFTR potentiator in patients with cystic fibrosis and the G551D mutation, N Engl J Med, 365, 1663, 10.1056/NEJMoa1105185 Accurso, 2010, Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation, N Engl J Med, 363, 1991, 10.1056/NEJMoa0909825 Davies, 2013, Efficacy and safety of ivacaftor in patients aged 6 to 11years with cystic fibrosis with a G551D mutation, Am J Respir Crit Care Med, 10.1164/rccm.201301-0153OC European Medicines Agency Sherrill, 1992, Continuous longitudinal regression equations for pulmonary function measures, Eur Respir J, 5, 452, 10.1183/09031936.93.05040452 Quanjer, 1993, Lung volumes and forced ventilatory flows, Eur Respir J, 16, 5, 10.1183/09041950.005s1693 Shah, 1995, Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment, Eur Respir J, 8, 954, 10.1183/09031936.95.08060954 Polenakovik, 2013, The use of ivacaftor in an adult with severe lung disease due to cystic fibrosis (ΔF508/G551D), J Cyst Fibros, 10.1016/j.jcf.2012.12.004 McKone, 2012, Long-term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D-CFTR mutation (abstract), J Cyst Fibros, 11, S13, 10.1016/S1569-1993(12)60042-3